[HTML][HTML] Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation

C Zhou, MM Tabb, EL Nelson, F Grün… - The Journal of …, 2006 - Am Soc Clin Investig
C Zhou, MM Tabb, EL Nelson, F Grün, S Verma, A Sadatrafiei, M Lin, S Mallick, BM Forman…
The Journal of clinical investigation, 2006Am Soc Clin Investig
While it has long been known that inflammation and infection reduce expression of hepatic
cytochrome P450 (CYP) genes involved in xenobiotic metabolism and that exposure to
xenobiotic chemicals can impair immune function, the molecular mechanisms underlying
both of these phenomena have remained largely unknown. Here we show that activation of
the nuclear steroid and xenobiotic receptor (SXR) by commonly used drugs in humans
inhibits the activity of NF-κB, a key regulator of inflammation and the immune response. NF …
While it has long been known that inflammation and infection reduce expression of hepatic cytochrome P450 (CYP) genes involved in xenobiotic metabolism and that exposure to xenobiotic chemicals can impair immune function, the molecular mechanisms underlying both of these phenomena have remained largely unknown. Here we show that activation of the nuclear steroid and xenobiotic receptor (SXR) by commonly used drugs in humans inhibits the activity of NF-κB, a key regulator of inflammation and the immune response. NF-κB target genes are upregulated and small bowel inflammation is significantly increased in mice lacking the SXR ortholog pregnane X receptor (PXR), thereby demonstrating a direct link between SXR and drug-mediated antagonism of NF-κB. Interestingly, NF-κB activation reciprocally inhibits SXR and its target genes whereas inhibition of NF-κB enhances SXR activity. This SXR/PXR–NF-κB axis provides a molecular explanation for the suppression of hepatic CYP mRNAs by inflammatory stimuli as well as the immunosuppressant effects of xenobiotics and SXR-responsive drugs. This mechanistic relationship has clinical consequences for individuals undergoing therapeutic exposure to the wide variety of drugs that are also SXR agonists.
The Journal of Clinical Investigation